Literature DB >> 7745471

Hemostatic changes in patients with brain tumors.

L Thoron1, E Arbit.   

Abstract

Abnormal hemostasis is a functional property of cancer. Hemostatic abnormalities are common in patients with systemic malignant disease and brain tumors. However, the incidence of thromboembolism is higher in patients with brain tumors than in those with systemic disease. This raises the question of whether or not hemostatic abnormalities found in the blood of the two groups of patients differs, suggesting different pathogeneses. The purpose of this report is to review abnormalities in blood and clinical manifestations of abnormal hemostasis found in brain tumors and cancer patients in an attempt to answer this question. Normal hemostasis, as currently understood, will be considered with an emphasis on features unique to the central nervous system.

Entities:  

Mesh:

Year:  1994        PMID: 7745471     DOI: 10.1007/BF01052885

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  124 in total

1.  Changes in endothelial-related coagulation proteins in response to venous occlusion.

Authors:  I Jennings; R J Luddington; P L Harper
Journal:  Thromb Haemost       Date:  1991-04-08       Impact factor: 5.249

2.  Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer.

Authors:  F Jänicke; M Schmitt; H Graeff
Journal:  Semin Thromb Hemost       Date:  1991-07       Impact factor: 4.180

Review 3.  Disseminated intravascular coagulation due to malignancy.

Authors:  R W Colman; R N Rubin
Journal:  Semin Oncol       Date:  1990-04       Impact factor: 4.929

4.  D-dimer and CA 125 levels in patients with ovarian cancer during antineoplastic therapy. Prognostic significance for the success of anti-cancer treatment.

Authors:  S S Mirshahi; E Pujade-Lauraine; C Soria; M Mirshahi; J Fretault; A Bernadou; J Soria
Journal:  Cancer       Date:  1992-05-01       Impact factor: 6.860

5.  The incidence and significance of thromboembolic complications in patients with high-grade gliomas.

Authors:  R Cheruku; E Tapazoglou; J Ensley; J A Kish; G D Cummings; M al-Sarraf
Journal:  Cancer       Date:  1991-12-15       Impact factor: 6.860

6.  Effect of human recombinant cytokines on the induction of macrophage procoagulant activity.

Authors:  I Schwager; T W Jungi
Journal:  Blood       Date:  1994-01-01       Impact factor: 22.113

Review 7.  High-dose chemotherapy with autologous bone marrow transplantation in the treatment of high grade astrocytomas in adults: therapeutic rationale and clinical experience.

Authors:  H A Fine; K H Antman
Journal:  Bone Marrow Transplant       Date:  1992-10       Impact factor: 5.483

Review 8.  Thrombosis and cancer.

Authors:  H F Dvorak
Journal:  Hum Pathol       Date:  1987-03       Impact factor: 3.466

Review 9.  Thrombosis in inherited deficiencies of antithrombin, protein C, and protein S.

Authors:  R D Rosenberg; K A Bauer
Journal:  Hum Pathol       Date:  1987-03       Impact factor: 3.466

10.  Glioblastoma infiltration into central nervous system tissue in vitro: involvement of a metalloprotease.

Authors:  P A Paganetti; P Caroni; M E Schwab
Journal:  J Cell Biol       Date:  1988-12       Impact factor: 10.539

View more
  11 in total

Review 1.  Brain metastases: 1995. A brief review.

Authors:  J B Posner
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

Review 2.  Medical management of patients with brain tumors.

Authors:  Patrick Y Wen; David Schiff; Santosh Kesari; Jan Drappatz; Debra C Gigas; Lisa Doherty
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

3.  Usefulness of 4D-CTA in the detection of cerebral dural sinus occlusion or stenosis with collateral pathways.

Authors:  Y Ono; K Abe; K Suzuki; H Iimura; S Sakai; S Uchiyama; Y Okada
Journal:  Neuroradiol J       Date:  2013-08-27

4.  Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study.

Authors:  M Napolitano; F Keime-Guibert; A Monjour; C Lafitte; A Ameri; P Cornu; P Broët; J Y Delattre
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Primary Brain Tumors.

Authors:  Neal S Parikh; Jaclyn E Burch; Hooman Kamel; Lisa M DeAngelis; Babak B Navi
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-06-21       Impact factor: 2.136

6.  Disseminated intravascular coagulation in a patient undergoing removal of metastatic brain tumor.

Authors:  Ki Seong Eom; Jong Moon Kim; Tae Young Kim
Journal:  J Korean Neurosurg Soc       Date:  2008-11-30

Review 7.  Venous thromboembolism in malignant gliomas.

Authors:  E O Jenkins; D Schiff; N Mackman; N S Key
Journal:  J Thromb Haemost       Date:  2009-11-13       Impact factor: 5.824

Review 8.  The management of thromboembolic disease in patients with central nervous system malignancies.

Authors:  Mary Ann Knovich; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2004-12

9.  Quantitative proteomic analysis of meningiomas for the identification of surrogate protein markers.

Authors:  Samridhi Sharma; Sandipan Ray; Aliasgar Moiyadi; Epari Sridhar; Sanjeeva Srivastava
Journal:  Sci Rep       Date:  2014-11-21       Impact factor: 4.379

10.  Meningioma and associated cerebral infarction in three dogs.

Authors:  Lisa Frank; Laura Burigk; Annika Lehmbecker; Peter Wohlsein; Alexandra Schütter; Nina Meyerhoff; Andrea Tipold; Jasmin Nessler
Journal:  BMC Vet Res       Date:  2020-06-05       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.